Ischemic Stroke, Stroke
Conditions
Brief summary
Magnesium has a neuroprotective role so the investigators aim to evaluate the role of intravenous magnesium sulphate in improving the clinical outcomes as assessed by the NIH Stroke Scale (NIHSS) in patients with acute ischemic stroke.
Interventions
DRUGMagnesium Sulfate
Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment. All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge.
Sponsors
Dow University of Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
45 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* Adults with a confirmed diagnosis of ischemic stroke on neurological examination and CT scan findings aged between 45 -95 years of age of either gender. * Adults presenting within a stroke onset of 24 hours.
Exclusion criteria
* Patients with confirmed diagnosis other than ischemic stroke (evidence of Intracranial bleed or space occupying lesion) * Subjects with systolic blood pressure less than 90mmHg * Presence of Bundle Branch block or atrioventricular block. * Serum Creatinine \> 3mg/dl * Respiratory failure (O2 saturation \<90% or Respiratory Rate \>24 or \<12) * Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement In Clinical Outcome As Measured By The improvement in NIH Stroke Scale After Infusion Of Magnesium Sulphate In Patients Suffering From Acute Ischemic Stroke. | 7 days |
Secondary
| Measure | Time frame |
|---|---|
| adverse effects | 7 days |
Contacts
Primary ContactHuda Naim, MBBS
Outcome results
None listed